TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01893554

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as nose drops (0.25 mL per nostril for a total of 0.5 mL).

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as nose drops (0.25 mL per nostril for a total of 0.5 mL).

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as nose drops (0.25 mL per nostril for a total of 0.5 mL).
Study: NCT03889821

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent-implemented Early Start Denver Model
Description: The Parent-implemented Early Start Denver Model (P-ESDM; Rogers et al., 2012) consists of 12 consecutive sessions, each session approximately 1 hour long, that promote parental ability to support and interact with their young children with autism spectrum disorder (ASD). Intervention sessions are conducted in the clinic setting by therapists trained to fidelity by ESDM-certified parent trainers. The manualized intervention has a detailed parent-training curriculum, a specific coaching intervention method, and a therapist fidelity measure. Therapists introduce skills through descriptions, interaction, modeling, coaching, and feedback.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parent-implemented Early Start Denver Model
Description: The Parent-implemented Early Start Denver Model (P-ESDM; Rogers et al., 2012) consists of 12 consecutive sessions, each session approximately 1 hour long, that promote parental ability to support and interact with their young children with autism spectrum disorder (ASD). Intervention sessions are conducted in the clinic setting by therapists trained to fidelity by ESDM-certified parent trainers. The manualized intervention has a detailed parent-training curriculum, a specific coaching intervention method, and a therapist fidelity measure. Therapists introduce skills through descriptions, interaction, modeling, coaching, and feedback.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction
Description: The Mindfulness Based Stress Reduction (MBSR) protocol is derived from the work by Dykens et al. (2014), which is based on the stress reduction and relaxation program (Kabat-Zinn, 1982, 1990). In this study, it is offered as 6 weekly sessions that run concurrent with the P-ESDM intervention. Participants work one-on-one with a therapist for instruction and practice in mindfulness skills as well as discussions of stress, coping, and homework assignments.
Study: NCT02816840

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET-CT
Description: Patients in this arm take radiotherapy positioning with PET-CT.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET-MRI
Description: Patients in this arm take radiotherapy positioning with PET-MRI.
Study: NCT02308462

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHIMPS intervention
Description: CHIMPs intervention (Family-Intervention composed of 8 Topic-related sessions over a period of 6 month, based on the evaluated manual: a preliminary talk with the family, two sessions with the parents, one session with each child, three sessions with the family).~The sessions are semi-structured and cover the topics illness and coping, education, family relationships and trusting attachement figures, social network and support of the Family. A detailed description of the procedure is found in the Manual (Wiegand-Grefe, Halverscheid \& Plass, 2011).
Study: NCT04127786

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Purified vero rabies vaccine - serum free - VRVg-2
Description: Pharmaceutical form: Freeze-dried Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Purified vero rabies vaccine - serum free - VRVg-2
Description: Pharmaceutical form: Freeze-dried Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Purified vero rabies vaccine - serum free - VRVg-2
Description: Pharmaceutical form: Freeze-dried Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Purified vero rabies vaccine - serum free - VRVg-2
Description: Pharmaceutical form: Freeze-dried Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Purified vero rabies vaccine - serum free - VRVg-2
Description: Pharmaceutical form: Freeze-dried Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Purified vero rabies vaccine - serum free - VRVg-2
Description: Pharmaceutical form: Freeze-dried Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Purified inactivated rabies vaccine - Verorab®
Description: Pharmaceutical form:Freeze-dried Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Purified inactivated rabies vaccine - Verorab®
Description: Pharmaceutical form:Freeze-dried Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Purified inactivated rabies vaccine - Imovax® Rabies
Description: Pharmaceutical form: Freeze-dried Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Purified inactivated rabies vaccine - Imovax® Rabies
Description: Pharmaceutical form: Freeze-dried Route of administration: Intramuscular
Study: NCT03406806

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gaitbox
Description: The walking path will be set according to the directions of the NIH toolbox 4 meter clinic walk test which includes marking the beginning and end of the walking path. A standard manual stopwatch will be used to record time. The examiner will demonstrate the task then instruct the participant to Walk at a comfortable pace and count down by saying: 3, 2, 1, go. The stop watch will be used to time the amount of time it takes to walk between the cones. Subjects will complete 3 timed trials. The time will be recorded in the log. Simultaneously, the Sprint System \[6\] will be operated according to manufacturers instructions. The Gaitbox will be set up at the end of the 4 meter walking path at a height of 4 feet from the floor. Times/speeds will be recorded on log sheet.
Study: NCT02034955

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Post-operative Adaptive Radiation Therapy
Study: NCT02747420

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NURO TM
Description: The lower extremity will be palpated and a needle insertion site will be identified 5 cm from the medial malleolus and posterior to the tibia. Between the posterior margin of the tibia and the soleus muscle, a 34-gauge acupuncture-like needle will be inserted 3-4 cm to the tibial nerve. A grounding pad will be placed on the bottom of the foot just below the smallest toe. An inactive grounding pad will be placed on top of the foot above the small toe to be consistent with the sham pad placement. The needle and grounding pad will be connected to the stimulator and the stimulation will be increased from 0 to 10 Milli-ampere. The needle will be taped. The electrical current will be set by the subject and the mA will be recorded. A 30 minute stimulation session will be given at 20 Hz.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: A needle will be inserted into the lower extremity approximately 5 cm cephalad from the medial malleolus and posterior to the tibia. A sham needle will be used a the tibial nerve insertion site. This will stimulate needle placement without puncturing the skin. The needle will be taped in place. The grounding pad from the transcutaneous electrical nerve stimulation (TENS) unit device will be placed on the bottom of the foot below the smallest toe. Another electrode will be placed on the top of the foot above the small toe for conduction. The TENS electrode will be connected to the TENS unit, at 20 Hz (the same as the PTNS group). The unit will be turned on and the stimulation will be increased to the subject's first sensory level. The subject will sense stimulation to either the bottom of the foot or the toe. the TENS unit will be on for a 30 minute test period. The TENS unit will be removed and the needle will be discarded.
Study: NCT01218074

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aggregometry+Thromboelastography
Description: Patients undergo standard thromboelastography and subsequent aggregometry to test effectiveness of residual antiaggregation drugs. Patients found to have altered value undergo optimization with desmopressin.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thromboelastography Alone
Description: Patients undergo standard of care Thromboelastography to evaluate overall coagulation performance.
Study: NCT02917031

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saxagliptin
Description: 5 mg or 2.5 mg, plain, yellow, biconvex, round, film-coated tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: 50 mg or 100 mg, gray capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match saxagliptin
Description: 2.5 mg or 5 mg, plain, yellow, biconvex, round, film-coated tablet
Study: NCT01828801

Intervention type: DEVICE
Intervention: Pinnacle Metal-on Metal
Description: All patients that are post-operative will have undergone total hip arthroplasty with the Pinnacle Metal-on-Metal device

Intervention type: DEVICE
Intervention: Pinnacle Metal-on Metal
Description: All patients that are post-operative will have undergone total hip arthroplasty with the Pinnacle Metal-on-Metal device

Intervention type: DEVICE
Intervention: Pinnacle Metal-on Metal
Description: All patients that are post-operative will have undergone total hip arthroplasty with the Pinnacle Metal-on-Metal device

Intervention type: DEVICE
Intervention: Pinnacle Metal-on Metal
Description: All patients that are post-operative will have undergone total hip arthroplasty with the Pinnacle Metal-on-Metal device
Study: NCT03613363

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Helix Ventilator
Description: The Helix ventilator is a non-FDA cleared ventilator device. The Helix ventilator has similar modalities to the Trilogy ventilator, which has FDA clearance. The Helix device has improved algorithms, controls, and features to enhance the therapy delivery. Additionally, Helix has an updated hardware platform which has been adequately tested to ensure that the device specifications are met. No pre-clinical or developmental clinical work was required because of Trilogy being the established predicate.
Study: NCT01560455

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: single stent
Description: single stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: two stent
Description: culotte
Study: NCT04648514

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Using of hydraulic lifter device for closed sinus lifting
Description: Using of recent closed minimally invasive technique (hydraulic left technique) by hydraulic lifter device for closed sinus lifting then evaluation of the amount of bone height gain will be done radiographically (by panorama and CBCT) after implant placement for patients with posterior edentulous maxilla .

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: patient satisfaction evaluation after using hydraulic lifter device
Description: Evaluation of patient satisfaction numerically will be done after using hydraulic lift technique by hydraulic lifter device for closed sinus lifting in posterior edentulous maxilla
Study: NCT01984450

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ACIC
Description: Autologous Collagen Induced Chondrogenesis (ACIC):~ACIC is a single stage arthroscopic procedure. It is done as a day case procedure. The cartilage defect is debrided and implanted with a collagen + fibrin gel mixture under CO2 insufflation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MCIC
Description: Mesenchymal Cell Induced Chondrogenesis (MCIC):~MCIC is a single stage arthroscopic procedure. It is done as a day case procedure. BMAC is harvested intraoperatively and concentrated. It is then mixed with a fibrin gel and implanted under CO2 insufflation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: implant with a collagen + fibrin gel mixture
Study: NCT03584243

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: A crosslinking with oxygen treatment
Description: A supplemental oxygen system during the cross linking will be used to apply filtered, humidified oxygen across the surface of the eye through a mask. The oxygen flow will be turned on immediately prior to initiation of irradiation, and will continue through the irradiation period. The supplemental oxygen flow will be shut off following completion of the programmed irradiation time.~All subjects will be evaluated at screening, day 3, and 1, 3, 6, 12 and 24 months after treatment. At the same time all the potential adverse effects will be relieved.
Study: NCT04552288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benralizumab
Description: All eligible patients will receive a benralizumab dose of 30 mg SC administered by a healthcare provider once every 4 weeks for the first 3 doses, followed by once every 8 weeks for 3 additional doses.
Study: NCT05399004

Intervention type: OTHER
Intervention: Survey Administration
Description: Complete surveys
Study: NCT00890682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKY0402
Description: Local infiltration of 8cc SKY0402

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Local infiltration of 8cc Placebo
Study: NCT03837093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ILT101
Description: Subcutaneous injections starting with induction course with once-daily administration for 5 consecutive days, followed by maintenance course with once every weeks administration during three weeks
Study: NCT03791047

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Balance Analysis
Description: Balance analysis is assessment method to estimate fall of risk and deterioration of postural control.
Study: NCT03837093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneous injections starting with induction course with once-daily administration for 5 consecutive days, followed by maintenance course with once every weeks administration during three weeks
Study: NCT01072071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: furosemide
Description: Loading dose: 0,5mg/kg Start continuous infusion at a dose of 0,1mg/kg/h and titrate according to diuretic response.~Target value for diuresis = (amount of fluids administered at inclusion/kg/h) + 0.5mL/kg/h If safety check is satisfactory: increase target diuresis with 1mL/kg/h per 4h to a maximum of (amount of fluids administered at inclusion/kg/h) + 2.5mL/kg/h Maximal dose of furosemide: 0.3mg/kg/h Safety check every 4h. Furosemide is administered for 24h. If safety checks are satisfactory, additional periods of 24 can be added up to a maximum of 72h.
Study: NCT03927794

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self-Assembling Peptide P11-4
Description: Self-Assembling Peptide P11-4 promotes subsurface biomimetic remineralization of enamel. It is a small peptide comprising 11 amino acids that when applied to an initial carious lesion diffuses into the body of the lesion, re-assembles itself into fibrils forming larger fibers and hence a 3-dimensional (3-D) matrix is formed. Natural remineralization driven by saliva is promoted through the surface of the P11-4 by increasing the surface area for calcium phosphate deposition. As a result, mineralization of the subsurface lesion occurs possibly due to the formation of de novo hydroxyapatite crystals on the surface of the P11-4 fibers.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-Assembling Peptide P11-4
Description: Self-Assembling Peptide P11-4 promotes subsurface biomimetic remineralization of enamel. It is a small peptide comprising 11 amino acids that when applied to an initial carious lesion diffuses into the body of the lesion, re-assembles itself into fibrils forming larger fibers and hence a 3-dimensional (3-D) matrix is formed. Natural remineralization driven by saliva is promoted through the surface of the P11-4 by increasing the surface area for calcium phosphate deposition. As a result, mineralization of the subsurface lesion occurs possibly due to the formation of de novo hydroxyapatite crystals on the surface of the P11-4 fibers.
Study: NCT04425837

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 convalescent plasma treatment
Description: Plasma transfusion of convalescent patients from COVID-19 with negative RT-PCR, and antibody titers of 1:160 or greater at a dose of 400ml distributed in two doses administered on the same day intravenous administration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard care
Description: Standard care according to guidelines and national regulations

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Standard care according to guidelines and national regulations
Study: NCT00799838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoprofen
Description: Formulation: oral solution 20mg/mL~Route of administration: oral~Dose regimen: 1 drop/Kg for children aged between 4 to 6 years old or 25 drops for children from 7 to 11 years old administered t.i.d

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Ketoprofen)
Description: Formulation: oral solution~Route of administration: oral~Dose regimen: 1 drop/Kg for children aged between 4 to 6 years old or 25 drops for children from 7 to 11 years old administered t.i.d

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Amoxicillin
Description: Formulation: suspension 125mg/5 mL~Route of administration: oral~Dose regimen: 20-40mg/Kg/day administered t.i.d
Study: NCT03791047

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance Analysis
Description: Balance analysis is assessment method to estimate fall of risk and deterioration of postural control.
Study: NCT01223391

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Abdominal binder
Description: External abdominal compression sequentially applied at 20 mmHg for 3 minutes, maximal tolerable level for 1.5 minutes and comfortable level for 2 minutes.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No abdominal binder
Description: Standing without abdominal binder for 3 minutes
Study: NCT02319278

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferumoxytol
Description: Infusion following between paired MRI scans

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferumoxytol
Description: Infusion following between paired MRI scans

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ferumoxytol
Description: Infusion following between paired MRI scans

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferumoxytol
Description: Infusion following between paired MRI scans
Study: NCT01078870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lexapro
Description: 10mg/cap 1\~2# QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cymbalta
Description: 30mg/cap 30\~60mg/QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 1\~2#/cap QD
Study: NCT04309617

Intervention type: PROCEDURE
Intervention: nephrectomy
Description: Surgery performed within the study period
Study: NCT02713009

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pregnancy multi-vitamin (including 10μg vitamin D3)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Pregnancy multi-vitamin (including 10μg vitamin D3)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 10μg vitamin D3

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 0μg vitamin D (placebo)
Study: NCT00979641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Study: NCT02065076

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium polystyrene sulfonate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lactose with carob gum
Study: NCT03666273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bapotulimab (BAY1905254)
Description: Intravenous administration of escalating doses of Bapotulimab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bapotulimab (BAY1905254) + Pembrolizumab (KEYTRUDA®)
Description: Intravenous administration of Bapotulimab of fixed dose (expansion), and of a fixed dose of pembrolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bapotulimab (BAY1905254) + Pembrolizumab (KEYTRUDA®)
Description: Intravenous administration of Bapotulimab of fixed dose (expansion), and of a fixed dose of pembrolizumab
Study: NCT01258309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olopatadine hydrochloride /ketorolac tromethamine fixed dose combination ophthalmic solution
Description: One drop of olopatadine hydrochloride/ketorolac tromethamine fixed dose combination ophthalmic solution administered to each eye, twice daily for 21 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olopatadine hydrochloride 0.1% ophthalmic solution
Description: One drop of olopatadine hydrochloride 0.1% ophthalmic solution administered to each eye, twice daily for 21 days.